Latest Publications

Share:

Why AI drug discovery deals are different from traditional pharma collaborations

Pharma companies have long collaborated with other organisations to bring new drugs to market. But what happens when their partner is an artificial intelligence (AI) company rather than another pharma business? Here, we...more

COVID-19 – the distinction between vaccines and vaccination

Vaccines - With thanks to a huge global scientific effort, we now have several COVID-19 vaccines that are safe and effective. - ...more

'Borderline' medical devices

The MHRA has recently released guidance to assist with the process of identifying whether a product is a ‘general medical device’ within Part II of the UK Medical Device Regulations 2002 (UK MDR 2002). Particularly with...more

Life Sciences Vision - The future of the UK Life Sciences sector

Last week, the UK Government (the Government) released its ‘Life Sciences Vision’ (the LSV), which sets out the Government and the life science sector’s ambitions for the next 10 years....more

Covid-19 – the UK’s vaccination programme so far (UPDATED)

As I said back in October, delivering a successful Covid-19 vaccine quickly was a huge challenge, but the diversity of the UK’s vaccine portfolio and the amendments made to the Human Medicines Regulations 2012 (HMRs) meant...more

Covid-19 – the UK’s vaccination programme so far

As I said back in October, delivering a successful Covid-19 vaccine quickly was a huge challenge, but the diversity of the UK’s vaccine portfolio and the amendments made to the Human Medicines Regulations 2012 (HMRs) meant...more

Covid-19 coronavirus – the UK’s preparation for a vaccine

The UK’s vaccine portfolio The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses: The vaccines are based on a range of vaccine technologies...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide